Marinus Pharmaceuticals Inc (NASDAQ:MRNS) – Research analysts at Cantor Fitzgerald increased their FY2019 earnings per share estimates for shares of Marinus Pharmaceuticals in a report issued on Thursday, November 7th, according to Zacks Investment Research. Cantor Fitzgerald analyst A. Young now forecasts that the biopharmaceutical company will earn ($0.95) per share for the year, up from their prior forecast of ($0.97). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. Cantor Fitzgerald also issued estimates for Marinus Pharmaceuticals’ FY2020 earnings at ($0.53) EPS.
A number of other equities analysts have also issued reports on MRNS. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $5.00 target price on shares of Marinus Pharmaceuticals in a research report on Monday, November 18th. ValuEngine lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, November 13th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Marinus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $8.65.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.02).
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its stake in Marinus Pharmaceuticals by 82.5% during the third quarter. Barclays PLC now owns 59,031 shares of the biopharmaceutical company’s stock worth $91,000 after buying an additional 26,680 shares in the last quarter. State Street Corp boosted its stake in Marinus Pharmaceuticals by 4.9% during the third quarter. State Street Corp now owns 931,433 shares of the biopharmaceutical company’s stock worth $1,434,000 after buying an additional 43,425 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in Marinus Pharmaceuticals during the second quarter worth $76,000. Morgan Stanley boosted its stake in Marinus Pharmaceuticals by 1,679.6% during the second quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock worth $780,000 after buying an additional 177,331 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Marinus Pharmaceuticals by 4.7% during the second quarter. Vanguard Group Inc. now owns 2,587,314 shares of the biopharmaceutical company’s stock worth $10,737,000 after buying an additional 115,294 shares in the last quarter. Hedge funds and other institutional investors own 57.99% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Recommended Story: What is a Swap?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.